Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer-Reference-Cited by-同舟云学术

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer

Published:2014-10 Issue:15 Volume:50 Page:2592-2601
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

van der Burg M.E.L.,Onstenk W.,Boere I.A.,Look M.,Ottevanger P.B.,de Gooyer D.,Kerkhofs L.G.M.^ORCID,Valster F.A.A.,Ruit J.B.,van Reisen A.G.P.M.,Goey S.H.,van der Torren A.M.E.,ten Bokkel Huinink D.^ORCID,Kok T.C.,Verweij J.,van Doorn H.C.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J Natl Cancer Inst,2003

2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

3. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer;Neijt;J Clin Oncol,2000

4. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study;Ozols;J Clin Oncol,2003

5. Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer;Piccart;Int J Gynecol Cancer,2003

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial;Frontiers in Immunology;2024-02-20

2. Ovarian cancer disease burden decreased in the United States from 1975 to 2018: A joinpoint and age-period-cohort analysis;Medicine;2023-12-01

3. Systemische Therapie der epithelialen serösen Ovarialkarzinome;Deutsche Zeitschrift für Onkologie;2023-12

4. Dose-dense regimen versus conventional three-weekly paclitaxel combination with carboplatin chemotherapy in first-line ovarian cancer treatment: a systematic review and meta-analysis;Journal of Ovarian Research;2023-07-10

5. Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum–Paclitaxel Chemotherapy: A Meta-Analysis;Clinical Oncology;2023-02